TMLL yields 200.00% · ABBV yields 3.06%● Live data
📍 TMLL pulled ahead of the other in Year 1
Combined, TMLL + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of TMLL + ABBV for your $10,000?
Tele Group Corp., a development stage Web 2.0 software company, develops Internet properties and applications primarily in the United States. The company offers a range of search, display, and interactive advertising products to reach and engage targeted consumers. Its products under development consist of NeXplore Search, a search engine, featuring a graphical user interface to allow the user to interact with the search results themselves and the advertisements that are presented to them, as well as to refine their search results by leveraging the collective intelligence of social communities of other users; and NeXplore Ads, a proprietary ad creation and management platform that enables marketers to create, manage, and modify, in real time, targeted interactive online advertising campaigns. The company's developing products also include HitLabel.com, a Web destination to offer music contests, and to provide musicians with viral tools for promoting their work and staying in tune with their fans; MyCircle.com, a universally accessible, application-agnostic social computing platform to offer users with a single, customizable interface for managing various facets of their online activity; and AdCircle, an interactive, graphical, and online classified advertising platform for buyers and sellers. The company was formerly known as NeXplore Corporation and changed its name to Tele Group Corp. in December 2020. Tele Group Corp was incorporated in 2007 and is headquartered in New York, New York.
Full TMLL Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.